Saturday 17 October 2026
Export ANEB’s income statement to Excel — free account
Anebulo Pharmaceuticals, Inc.
ANEB Healthcare Biotechnology
In the quarter to December 2025, EPS grew 44.4% and free cash flow grew 6.58%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.00
0.31
−100.00%
Follow ANEB
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Older periods | |
|---|---|---|---|---|---|
| (69.69%) | (145.11%) | (109.69%) | (83.37%) |
+8 more TTM periods Free account |
|
| (63.17%) | (128.22%) | (104.63%) | (76.88%) | ||
ROIC |
0.00% | 0.00% | (19,215.63%) | (2,817.98%) | |
Return on Tangible Assets |
(102.45%) | (88.20%) | (73.94%) | (57.98%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.14) | (0.14) | (0.19) | (0.16) | |
Free Cash Flow |
(5.84) | (5.93) | (6.35) | (6.75) | |
| Other line items | |||||
Cash ROIC |
(34.40%) | (29.53%) | (27.27%) | (25.24%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(30.61) | (26.70) | (24.15) | (19.40) | |
Operating CF/Net income |
0.73 | 0.70 | 0.75 | 0.88 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.14) | (0.14) | (0.19) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates